Overview
Intellia Therapeutics, Inc., based in the United States, operates primarily in the biotechnology industry, focusing on developing therapeutic products using CRISPR/Cas9 technology, a pioneering method in gene editing. The company is dedicated to creating in vivo treatments that amend defective genes from within the human body and ex vivo solutions for engineered cells targeting various illnesses. A significant project in Intellia's portfolio is its CRISPR/Cas9-based development programs targeting transthyretin amyloidosis, a rare, progressively debilitating disease. Through strategic collaborations and a robust development pipeline, Intellia Therapeutics, Inc. aims to leverage the transformative potential of genomics to produce therapeutic products that significantly improve patient outcomes in genetic diseases and oncology.
Basic Stats
The share price of Intellia Therapeutics, Inc. as of September 5, 2025 is $12.07 / share. This is an increase of 6.30% from the prior week. The market cap (or net worth) of Intellia Therapeutics, Inc. as of September 5, 2025 is $1,271.34 MM.
The Factor Analysis chart (below right) shows a view of Intellia Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 1,271.34 MM |
| EV | 1,115.17 MM |
| Shares Out. | 105.33 MM |
| Earnings Date | |
| EPS (TTM) | -4.56 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.47 |
| Short Shares Avail. | 0.75 MM |
| Short Interest | 27.73 MM |
| Short Float | 27.21 % |
| Days to Cover | 7.48 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -42.33 % |
| Volatility (1 yr) | 0.80 |
| Beta | 1.87 |
| Sharpe Ratio (1 yr) | -0.58 |
| Sortino Ratio (1 yr) | -0.92 |
| PE Ratio | -2.65 |
| Price/Book | 1.78 |
| Price/TBV | 1.78 |
| Book/Market | 0.56 |
| EBIT/EV | -0.43 |
| EBIT(3yr avg)/EV | -0.43 |
| ROA | -0.40 |
| ROE | -0.49 |
| ROIC | -0.59 |
| CROIC | 0.03 |
| OCROIC | -0.51 |
| Implied Volatility | 79.31 % |
| Put/Call OI Ratio | 0.26 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Intellia Therapeutics, Inc. is $33.84. The forecasts range from a low of $7.07 to a high of $111.30. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Intellia Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-06 | Credit Suisse | Outperform | Maintains | |
| 2022-12-02 | SVB Leerink | Outperform | Maintains | |
| 2022-11-15 | Chardan Capital | Buy | Maintains | |
| 2022-11-04 | Raymond James | Outperform | Maintains | |
| 2022-11-04 | Morgan Stanley | Overweight | Maintains | |
| 2022-11-04 | EF Hutton | Buy | Maintains | |
| 2022-11-04 | Credit Suisse | Outperform | Maintains | |
| 2022-11-04 | Chardan Capital | Buy | Maintains | |
| 2022-11-01 | EF Hutton | Buy | Initiate | |
| 2022-10-11 | Morgan Stanley | Overweight | Initiate | |
| 2022-09-21 | JP Morgan | Overweight | Initiate | |
| 2022-09-19 | SVB Leerink | Outperform | Maintains | |
| 2022-09-19 | JMP Securities | Market Outperform | Maintains | |
| 2022-09-01 | Citigroup | Sell | Initiate | |
| 2022-08-05 | SVB Leerink | Outperform | Maintains | |
| 2022-08-05 | Chardan Capital | Buy | Maintains | |
| 2022-06-17 | BMO Capital | Market Perform | Initiate | |
| 2022-06-16 | B of A Securities | Buy | Initiate | |
| 2022-05-24 | Goldman Sachs | Buy | Maintains | |
| 2022-05-09 | Oppenheimer | Outperform | Maintains | |
| 2022-05-09 | JMP Securities | Market Outperform | Maintains | |
| 2022-05-06 | Raymond James | Outperform | Maintains | |
| 2022-05-06 | Credit Suisse | Outperform | Maintains | |
| 2022-04-28 | Credit Suisse | Outperform | Initiate | |
| 2022-03-07 | Brookline Capital | Hold | Buy | Upgrade |
| 2022-03-01 | Chardan Capital | Buy | Maintains | |
| 2022-02-18 | William Blair | Outperform | Initiate | |
| 2022-02-14 | Brookline Capital | Hold | Initiate | |
| 2022-02-07 | Oppenheimer | Perform | Outperform | Upgrade |
| 2022-01-31 | Cowen & Co. | Outperform | Initiate | |
| 2022-01-07 | Piper Sandler | Overweight | Initiate | |
| 2022-01-07 | JMP Securities | Market Outperform | Maintains | |
| 2021-11-05 | Oppenheimer | Perform | Maintains | |
| 2021-11-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-10-05 | Guggenheim | Buy | Initiate | |
| 2021-09-24 | Stifel | Buy | Initiate | |
| 2021-08-06 | Raymond James | Outperform | Maintains | |
| 2021-08-06 | Oppenheimer | Perform | Maintains | |
| 2021-08-06 | JMP Securities | Market Outperform | Maintains | |
| 2021-08-06 | Goldman Sachs | Buy | Maintains | |
| 2021-08-06 | Chardan Capital | Buy | Maintains | |
| 2021-06-29 | Raymond James | Outperform | Maintains | |
| 2021-06-29 | Oppenheimer | Perform | Maintains | |
| 2021-06-28 | Wedbush | Neutral | Maintains | |
| 2021-06-28 | Truist Securities | Buy | Maintains | |
| 2021-06-28 | Roth Capital | Buy | Maintains | |
| 2021-06-28 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-06-28 | Goldman Sachs | Buy | Maintains | |
| 2021-06-28 | Chardan Capital | Buy | Maintains | |
| 2021-06-28 | Barclays | Overweight | Maintains | |
| 2021-06-23 | JMP Securities | Market Outperform | Maintains | |
| 2021-06-23 | Baird | Neutral | Maintains | |
| 2021-06-11 | HC Wainwright & Co. | Buy | Initiate | |
| 2021-05-07 | Roth Capital | Neutral | Buy | Upgrade |
| 2021-05-04 | RBC Capital | Outperform | Initiate | |
| 2021-03-04 | JMP Securities | Outperform | Initiate | |
| 2021-02-10 | Chardan Capital | Buy | Maintains | |
| 2021-01-08 | Raymond James | Outperform | Maintains | |
| 2020-12-22 | Baird | Outperform | Neutral | Downgrade |
| 2020-10-27 | Truist Securities | Buy | Initiate | |
| 2020-10-14 | Wells Fargo | Overweight | Initiate | |
| 2020-09-18 | Goldman Sachs | Buy | Initiate | |
| 2020-06-02 | Credit Suisse | Neutral | Maintains | |
| 2020-02-28 | Oppenheimer | Perform | Outperform | Upgrade |
| 2020-02-14 | Wedbush | Outperform | Neutral | Downgrade |
| 2019-11-01 | Raymond James | Market Perform | Outperform | Upgrade |
| 2019-07-09 | Baird | Outperform | Initiate | |
| 2019-06-10 | Roth Capital | Neutral | Initiate | |
| 2019-05-03 | Wedbush | Neutral | Outperform | Upgrade |
| 2019-04-12 | Evercore ISI Group | Outperform | Initiate | |
| 2019-02-08 | BTIG Research | Buy | Initiate | |
| 2018-11-28 | Leerink Swann | Outperform | Initiate | |
| 2018-11-02 | Wedbush | Outperform | Neutral | Downgrade |
| 2018-09-21 | Raymond James | Market Perform | Initiate | |
| 2018-05-15 | Chardan Capital | Neutral | Buy | Upgrade |
| 2018-03-08 | JMP Securities | Market Outperform | Initiate | |
| 2018-03-07 | Barclays | Overweight | Overweight | Maintains |
| 2017-11-03 | Credit Suisse | Outperform | Maintains | |
| 2017-11-01 | Jefferies | Buy | Maintains | |
| 2017-09-07 | Barclays | Overweight | Initiate | |
| 2017-08-29 | Chardan Capital | Buy | Neutral | Downgrade |
| 2017-08-02 | Chardan Capital | Buy | Maintains | |
| 2017-07-18 | Oppenheimer | Perform | Initiate | |
| 2017-03-28 | Chardan Capital | Buy | Initiate | |
| 2016-09-29 | Janney Capital | Buy | Initiate | |
| 2016-09-28 | Janney Capital | Buy | Initiate | |
| 2016-08-05 | Leerink Swann | Market Perform | Outperform | Upgrade |
| 2016-08-05 | Jefferies | Hold | Buy | Upgrade |
| 2016-05-31 | Wedbush | Outperform | Initiate | |
| 2016-05-31 | Leerink Swann | Market Perform | Initiate | |
| 2016-05-31 | Jefferies | Hold | Initiate | |
| 2016-05-31 | Credit Suisse | Outperform | Initiate | |
| 2023-01-23 | SVB Leerink | Outperform | Maintains | |
| 2023-01-04 | Wells Fargo | Overweight | Maintains | |
| 2023-01-19 | JMP Securities | Market Outperform | Market Perform | Downgrade |
| 2023-01-24 | Citigroup | Sell | Neutral | Upgrade |
| 2023-02-01 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-02-27 | Chardan Capital | Buy | Maintains | |
| 2023-02-24 | Credit Suisse | Outperform | Maintains | |
| 2023-02-24 | Oppenheimer | Outperform | Maintains | |
| 2023-02-24 | Baird | Neutral | Maintains | |
| 2023-02-24 | EF Hutton | Buy | Maintains | |
| 2023-02-24 | Raymond James | Outperform | Maintains | |
| 2023-03-14 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2023-03-21 | Bernstein | Outperform | Initiate | |
| 2023-03-31 | JP Morgan | Overweight | Maintains | |
| 2023-05-05 | Raymond James | Outperform | Maintains | |
| 2023-05-05 | BMO Capital | Outperform | Maintains | |
| 2023-04-13 | Canaccord Genuity | Buy | Initiate | |
| 2023-05-08 | Citigroup | Neutral | Maintains | |
| 2023-05-08 | Morgan Stanley | Overweight | Maintains | |
| 2023-05-08 | Oppenheimer | Outperform | Maintains | |
| 2023-06-13 | Chardan Capital | Buy | Buy | Maintains |
| 2023-06-13 | Credit Suisse | Outperform | Outperform | Reiterate |
| 2023-06-13 | B of A Securities | Buy | Buy | Maintains |
| 2023-11-10 | Raymond James | Outperform | Outperform | Maintains |
| 2023-08-04 | Citigroup | Neutral | Neutral | Maintains |
| 2023-08-29 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-13 | Oppenheimer | Outperform | Outperform | Maintains |
| 2023-11-13 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-02-15 | Wolfe Research | Peer Perform | Initiate | |
| 2023-08-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-08-07 | Barclays | Overweight | Overweight | Maintains |
| 2023-08-04 | Barclays | Overweight | Overweight | Maintains |
| 2023-09-13 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-10 | BMO Capital | Outperform | Outperform | Maintains |
| 2023-11-10 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-11-10 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-08-07 | Chardan Capital | Buy | Buy | Reiterate |
| 2023-08-07 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-04-23 | Wedbush | Neutral | Neutral | Reiterate |
| 2024-02-23 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2024-02-23 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-06-04 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-05-10 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-05-10 | Citigroup | Neutral | Neutral | Maintains |
| 2024-06-24 | Truist Securities | Buy | Buy | Maintains |
| 2024-06-24 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-27 | Canaccord Genuity | Buy | Buy | Maintains |
| 2024-06-18 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-03-05 | HC Wainwright & Co. | Buy | Initiate | |
| 2024-08-09 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-11-08 | Barclays | Overweight | Overweight | Maintains |
| 2024-10-25 | Baird | Neutral | Neutral | Maintains |
| 2024-10-24 | Chardan Capital | Buy | Buy | Maintains |
| 2024-09-11 | Stifel | Buy | Buy | Maintains |
| 2025-05-29 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-28 | JP Morgan | Overweight | Neutral | Downgrade |
| 2024-10-25 | Citigroup | Neutral | Neutral | Maintains |
| 2024-10-25 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-01-10 | BMO Capital | Outperform | Outperform | Maintains |
| 2025-01-10 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-11-18 | Chardan Capital | Buy | Buy | Maintains |
| 2024-11-18 | Wedbush | Neutral | Neutral | Reiterate |
| 2024-11-18 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-08-12 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-09-17 | Jones Trading | Buy | Initiate | |
| 2025-02-28 | Chardan Capital | Buy | Buy | Maintains |
| 2025-02-28 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-02-28 | Citigroup | Neutral | Neutral | Maintains |
| 2024-11-19 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-01-14 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-01-27 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2025-02-28 | Barclays | Overweight | Overweight | Maintains |
| 2024-09-19 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-01-13 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-11-11 | Oppenheimer | Outperform | Outperform | Maintains |
| 2025-08-08 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-08-08 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-06-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-04 | Truist Securities | Buy | Buy | Maintains |
| 2025-04-21 | Wolfe Research | Peer Perform | Outperform | Upgrade |
| 2025-05-12 | Guggenheim | Buy | Buy | Maintains |
| 2025-05-19 | Wedbush | Neutral | Neutral | Reiterate |
| 2025-05-09 | Chardan Capital | Buy | Buy | Maintains |
| 2025-05-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-03 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-05-09 | Citigroup | Neutral | Neutral | Maintains |
| 2025-08-11 | Chardan Capital | Buy | Buy | Maintains |
| 2025-08-08 | HC Wainwright & Co. | Buy | Buy | Maintains |
